JP2024519917A5 - - Google Patents
Info
- Publication number
- JP2024519917A5 JP2024519917A5 JP2023571950A JP2023571950A JP2024519917A5 JP 2024519917 A5 JP2024519917 A5 JP 2024519917A5 JP 2023571950 A JP2023571950 A JP 2023571950A JP 2023571950 A JP2023571950 A JP 2023571950A JP 2024519917 A5 JP2024519917 A5 JP 2024519917A5
- Authority
- JP
- Japan
- Prior art keywords
- pharmaceutical composition
- composition according
- pharmaceutically acceptable
- subject
- dosage form
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202163191142P | 2021-05-20 | 2021-05-20 | |
| US63/191,142 | 2021-05-20 | ||
| PCT/US2022/030111 WO2022246114A2 (en) | 2021-05-20 | 2022-05-19 | Pharmaceutical compositions comprising a ryanodine receptor modulator and uses thereof |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2024519917A JP2024519917A (ja) | 2024-05-21 |
| JP2024519917A5 true JP2024519917A5 (cg-RX-API-DMAC7.html) | 2025-05-23 |
Family
ID=84141833
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023571950A Pending JP2024519917A (ja) | 2021-05-20 | 2022-05-19 | リアノジン受容体モジュレーターを含む医薬組成物およびそれらの使用 |
Country Status (11)
| Country | Link |
|---|---|
| US (4) | US11717526B2 (cg-RX-API-DMAC7.html) |
| EP (1) | EP4340861A4 (cg-RX-API-DMAC7.html) |
| JP (1) | JP2024519917A (cg-RX-API-DMAC7.html) |
| KR (1) | KR20240040681A (cg-RX-API-DMAC7.html) |
| CN (1) | CN117750966A (cg-RX-API-DMAC7.html) |
| AU (1) | AU2022279235A1 (cg-RX-API-DMAC7.html) |
| BR (1) | BR112023024170A2 (cg-RX-API-DMAC7.html) |
| CA (1) | CA3176718A1 (cg-RX-API-DMAC7.html) |
| IL (1) | IL308481A (cg-RX-API-DMAC7.html) |
| MX (1) | MX2023013744A (cg-RX-API-DMAC7.html) |
| WO (1) | WO2022246114A2 (cg-RX-API-DMAC7.html) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2022150603A1 (en) * | 2021-01-08 | 2022-07-14 | Armgo Pharma, Inc. | Crystalline forms of a ryanodine receptor modulator and uses thereof |
| EP4433062A4 (en) * | 2021-11-16 | 2025-10-22 | Rycarma Therapeutics Inc | THERAPEUTIC COMPOUNDS |
Family Cites Families (18)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPS5920219A (ja) * | 1982-07-26 | 1984-02-01 | Shin Etsu Chem Co Ltd | 腸溶性コ−テイング製剤の製造方法 |
| US4775536A (en) * | 1986-02-24 | 1988-10-04 | Bristol-Myers Company | Enteric coated tablet and process for making |
| US8022058B2 (en) | 2000-05-10 | 2011-09-20 | The Trustees Of Columbia University In The City Of New York | Agents for preventing and treating disorders involving modulation of the RyR receptors |
| US7718644B2 (en) * | 2004-01-22 | 2010-05-18 | The Trustees Of Columbia University In The City Of New York | Anti-arrhythmic and heart failure drugs that target the leak in the ryanodine receptor (RyR2) and uses thereof |
| JP4414237B2 (ja) | 2002-03-20 | 2010-02-10 | テバ ファーマシューティカル インダストリーズ リミティド | ケチアピンヘミフマレートの結晶形 |
| US8710045B2 (en) | 2004-01-22 | 2014-04-29 | The Trustees Of Columbia University In The City Of New York | Agents for preventing and treating disorders involving modulation of the ryanodine receptors |
| US7704990B2 (en) | 2005-08-25 | 2010-04-27 | The Trustees Of Columbia University In The City Of New York | Agents for preventing and treating disorders involving modulation of the RyR receptors |
| US20100297226A1 (en) * | 2006-06-01 | 2010-11-25 | Dexcel Pharma Technologies Ltd. | Multiple unit pharmaceutical formulation |
| WO2008060332A2 (en) | 2006-06-02 | 2008-05-22 | The Trustees Of Columbia University In The City Of New York | Methods for treating or reducing muscle fatigue |
| WO2008021439A2 (en) | 2006-08-17 | 2008-02-21 | The Trustees Of Columbia University In The City Of New York | Compositions and methods for treatment of cardiac hypertrophy |
| WO2008021432A2 (en) | 2006-08-17 | 2008-02-21 | The Trustees Of Columbia University In The City Of New York | Compositions and methods for treatment of conditions affecting the nervous system |
| WO2008144483A2 (en) | 2007-05-18 | 2008-11-27 | Armgo Pharma, Inc. | Agents for treating disorders involving modulation of ryanodine receptors |
| EA028108B1 (ru) | 2008-03-03 | 2017-10-31 | Армго Фарма, Инк. | Способ получения бензотиазепинов из гамма-аминоалкилбензолов |
| WO2012037105A1 (en) | 2010-09-14 | 2012-03-22 | The Trustees Of Columbia University In The City Of New York | Methods of treating, ameliorating or preventing stress-induced neuronal disorders and diseases |
| EP2708535A1 (en) * | 2012-05-11 | 2014-03-19 | Les Laboratoires Servier | Agents for treating disorders involving modulation of ryanodine receptors |
| WO2015106268A1 (en) * | 2014-01-13 | 2015-07-16 | Ironwood Pharmaceuticals, Inc. | USE OF sGC STIMULATORS FOR THE TREATMENT OF NEUROMUSCULAR DISORDERS |
| WO2016109596A1 (en) | 2014-12-30 | 2016-07-07 | Myotherix, Inc. | Novel calcium modulators |
| JP6954927B2 (ja) * | 2016-02-09 | 2021-10-27 | アルビレオ・アクチボラグ | 経口コレスチラミン製剤及びその使用 |
-
2022
- 2022-05-19 JP JP2023571950A patent/JP2024519917A/ja active Pending
- 2022-05-19 EP EP22805512.5A patent/EP4340861A4/en active Pending
- 2022-05-19 AU AU2022279235A patent/AU2022279235A1/en active Pending
- 2022-05-19 US US17/748,886 patent/US11717526B2/en active Active
- 2022-05-19 CA CA3176718A patent/CA3176718A1/en active Pending
- 2022-05-19 WO PCT/US2022/030111 patent/WO2022246114A2/en not_active Ceased
- 2022-05-19 IL IL308481A patent/IL308481A/en unknown
- 2022-05-19 BR BR112023024170A patent/BR112023024170A2/pt unknown
- 2022-05-19 MX MX2023013744A patent/MX2023013744A/es unknown
- 2022-05-19 CN CN202280050798.3A patent/CN117750966A/zh active Pending
- 2022-05-19 KR KR1020237044065A patent/KR20240040681A/ko active Pending
-
2023
- 2023-07-13 US US18/221,784 patent/US12059426B2/en active Active
- 2023-07-25 US US18/225,849 patent/US12161650B2/en active Active
-
2024
- 2024-10-31 US US18/933,539 patent/US20250302847A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US20220168255A1 (en) | Pharmaceutical composition containing dimethyl fumarate for administration at a low daily dose | |
| TWI468191B (zh) | 有機化合物之調配物 | |
| EP2205279B1 (en) | Pharmaceutical combination of aliskiren and valsartan | |
| HUP0204409A2 (en) | Sustained release ranolazine pharmaceutical compositions | |
| CN101132777A (zh) | 用于睡眠障碍的药物组合物 | |
| HUP0104088A2 (hu) | Késleltetett felszabadulású ranolazinkészítmények alkalmazása | |
| JP2007509155A5 (cg-RX-API-DMAC7.html) | ||
| US20030147957A1 (en) | Dual release formulation comprising levodopa ethyl ester and a decarboxylase inhibitor in immediate release layer with levodopa ethyl ester and a decarboxylase inhibitor in a controlled release core | |
| JP2019529570A (ja) | ミドドリンの組成物およびその使用方法 | |
| CA2606740A1 (en) | Quinine-containing controlled-release formulations | |
| CN114096530B (zh) | 一种复合物的药物组合物及其制备方法 | |
| JP5362556B2 (ja) | アリスキレンおよびヒドロクロロチアジドのガレヌス製剤 | |
| US20110123612A1 (en) | Pharmaceutical preparation containing non-dihydropyridine calcium channel blocker and angiotensin-2 receptor blocker | |
| US20240366514A1 (en) | Pharmaceutical compositions of ozanimod | |
| CN101843892B (zh) | 包括依那普利速释部分和非洛地平缓释部分的药物组合物制剂 | |
| US20110195117A1 (en) | Controlled release compositions of ropinirole | |
| JP2024539735A5 (cg-RX-API-DMAC7.html) | ||
| KR20090107960A (ko) | 심혈관계 질환 치료용 약제학적 제제 | |
| HK1161125B (en) | Galenic formulations comprising aliskiren |